Anticipated $-0.48 EPS for Allena Pharmaceuticals, Inc. (ALNA) as of December, 13

On December, 13. Investors expect Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) to report its quarterly earnings, according to Zacks. Analysts have anticipation on stock’s earnings per share of $-0.48. That’s up 86.25 % from last year’s $-3.49 earnings per share. After $-0.42 EPS report previous quarter, Wall Street now forecasts 14.29 % negative EPS growth of Allena Pharmaceuticals, Inc.. The stock increased 8.58% or $0.68 during the last trading session, hitting $8.61.Allena Pharmaceuticals, Inc. is after having 0.00% since November 9, 2017. ALNA has 58,311 volume or 16.51% up from normal. The stock underperformed the S&P500 by 15.62%.

Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States.The company has $178.68 million market cap. The company's lead product candidate includes ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.Last it reported negative earnings. It is also involved in developing ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases.

More recent Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) news were posted by, and The first one has “Allena Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update” as a title and was posted on November 07, 2018. The next is “Allena Pharmaceuticals Highlights Ongoing Efforts to Address Rare and Severe Metabolic Disorders Affecting the …” on October 18, 2018. And last was posted on November 06, 2018, called “Allena Pharmaceuticals to Present at Upcoming Investor Conferences in November”.

Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.